Prognostic impact of chromogranin A in patients with acute heart failure
Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarker...
Saved in:
Published in | Journal of yeungnam medical science Vol. 38; no. 4; pp. 337 - 343 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Yeungnam University College of Medicine
01.10.2021
영남대학교 의과대학 |
Subjects | |
Online Access | Get full text |
ISSN | 2384-0293 2384-0293 2799-8010 |
DOI | 10.12701/yujm.2020.00843 |
Cover
Abstract | Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients. |
---|---|
AbstractList | Background Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure. Methods We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization. Results In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors. Conclusion The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients. Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure. Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization. Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors. Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients. KCI Citation Count: 0 Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.BACKGRUOUNDChromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.METHODSWe retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.RESULTSIn-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.CONCLUSIONThe prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients. Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure. We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization. In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors. The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients. |
Author | Park, Hun Sik Kim, Hong Nyun Kim, Hyeon Jeong Yang, Dong Heon Park, Bo Eun Lee, Jang Hoon Chae, Shung Chull Cho, Yongkeun Jang, Se Yong Park, Yoon Jung Bae, Myung Hwan |
Author_xml | – sequence: 1 givenname: Hong Nyun orcidid: 0000-0002-9903-1848 surname: Kim fullname: Kim, Hong Nyun – sequence: 2 givenname: Dong Heon orcidid: 0000-0002-1646-6126 surname: Yang fullname: Yang, Dong Heon – sequence: 3 givenname: Bo Eun orcidid: 0000-0002-5245-9863 surname: Park fullname: Park, Bo Eun – sequence: 4 givenname: Yoon Jung orcidid: 0000-0001-5132-226X surname: Park fullname: Park, Yoon Jung – sequence: 5 givenname: Hyeon Jeong orcidid: 0000-0002-3496-3142 surname: Kim fullname: Kim, Hyeon Jeong – sequence: 6 givenname: Se Yong orcidid: 0000-0002-4981-879X surname: Jang fullname: Jang, Se Yong – sequence: 7 givenname: Myung Hwan orcidid: 0000-0001-7677-4895 surname: Bae fullname: Bae, Myung Hwan – sequence: 8 givenname: Jang Hoon orcidid: 0000-0002-7101-0236 surname: Lee fullname: Lee, Jang Hoon – sequence: 9 givenname: Hun Sik orcidid: 0000-0001-7138-1494 surname: Park fullname: Park, Hun Sik – sequence: 10 givenname: Yongkeun orcidid: 0000-0001-9455-0190 surname: Cho fullname: Cho, Yongkeun – sequence: 11 givenname: Shung Chull orcidid: 0000-0002-9871-6976 surname: Chae fullname: Chae, Shung Chull |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34233402$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002768387$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNqFUctv0zActtAQG2N3TihHOLT4FT8uSNUErNIkEBpny7Gd1l1iBzvZ1P8eNx3TxgEu_ln29_Dn7zU4CTE4AN4iuESYQ_RxP-36JYYYLiEUlLwAZ5gIuoBYkpMn-1NwkfMOQogx4hihV-CUUEwIhfgMXH1PcRNiHr2pfD9oM1axrcw2xT5ukg4-VKuqLIMevQtjru79uK20mUZXbZ1OY9Vq303JvQEvW91ld_Ewz8HPL59vLq8W19--ri9X1wtDKCILTKmljDaUcW6lpKJhXCLecsk5F6JprWSWOiKhaDU02GLdCqKRqyEmxhhyDj4cdUNq1a3xKmo_z01Ut0mtftyslRScMlYX7PqItVHv1JB8r9N-JswHMW1USeBN5xRrIdFCcmprRBGDmlkt6zIdQbU1TdFCR60pDHp_r7vuURBBNReiDoWoQyFqLqRwPh05w9T0zprygUl3zx7y_Cb4bclxpwQTggteBN4_CKT4a3J5VL3PxnWdDi5OWeGaygKlVBTou6dejyZ_qi4AdgSYFHNOrlXGj6XVeLD23b9SwL-I_w3-G9AGzXk |
CitedBy_id | crossref_primary_10_3390_jpm12060898 crossref_primary_10_3390_jcm12113834 |
Cites_doi | 10.1016/j.amjcard.2016.05.018 10.4070/kcj.2017.0009 10.3346/jkms.2019.34.e133 10.4070/kcj.2018.0349 10.4070/kcj.2018.0373 10.1093/eurjhf/hfq055 10.1111/j.1527-5299.2004.03310.x 10.1152/ajpendo.1991.260.2.e243 10.1053/euhj.2001.2977 10.4070/kcj.2018.0351 10.1080/08880010802435393 10.1093/eurheartj/ehn513 10.1016/j.ahj.2006.05.008 10.4070/kcj.2016.0419 |
ContentType | Journal Article |
Copyright | Copyright © 2021 Yeungnam University College of Medicine 2021 |
Copyright_xml | – notice: Copyright © 2021 Yeungnam University College of Medicine 2021 |
DBID | AAYXX CITATION NPM 7X8 5PM ADTOC UNPAY DOA ACYCR |
DOI | 10.12701/yujm.2020.00843 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall Directory of Open Access Journals (DOAJ) Korean Citation Index |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Chromogranin A in acute heart failure |
EISSN | 2384-0293 2799-8010 |
EndPage | 343 |
ExternalDocumentID | oai_kci_go_kr_ARTI_9874665 oai_doaj_org_article_6f03a8974d514160a6da9560ae315dcb 10.12701/yujm.2020.00843 PMC8688787 34233402 10_12701_yujm_2020_00843 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Kyungpook National University |
GroupedDBID | 8JR AAYXX ACYCR ADBBV ALMA_UNASSIGNED_HOLDINGS BCNDV CITATION EF. GROUPED_DOAJ HYE M~E PGMZT RPM NPM 7X8 5PM ADTOC UNPAY HZB |
ID | FETCH-LOGICAL-c3413-244d464b4677d9948b67917f7977788bfd96d4e3908fa0c2d2af83a1e5023ccc3 |
IEDL.DBID | DOA |
ISSN | 2384-0293 |
IngestDate | Sat Jan 04 03:31:02 EST 2025 Wed Aug 27 00:47:01 EDT 2025 Wed Oct 01 16:01:44 EDT 2025 Thu Aug 21 18:23:35 EDT 2025 Fri Jul 11 06:51:53 EDT 2025 Thu Jan 02 22:54:13 EST 2025 Thu Apr 24 23:07:30 EDT 2025 Tue Jul 01 04:12:21 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Heart failure Biomarkers Chromogranin A Prognosis |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. cc-by-nc |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3413-244d464b4677d9948b67917f7977788bfd96d4e3908fa0c2d2af83a1e5023ccc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 http://www.e-yujm.org/journal/view.php?doi=10.12701/yujm.2020.00843 |
ORCID | 0000-0002-7101-0236 0000-0002-1646-6126 0000-0002-9903-1848 0000-0001-9455-0190 0000-0002-3496-3142 0000-0001-5132-226X 0000-0002-5245-9863 0000-0002-4981-879X 0000-0001-7138-1494 0000-0002-9871-6976 0000-0001-7677-4895 |
OpenAccessLink | https://doaj.org/article/6f03a8974d514160a6da9560ae315dcb |
PMID | 34233402 |
PQID | 2549688448 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_9874665 doaj_primary_oai_doaj_org_article_6f03a8974d514160a6da9560ae315dcb unpaywall_primary_10_12701_yujm_2020_00843 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8688787 proquest_miscellaneous_2549688448 pubmed_primary_34233402 crossref_citationtrail_10_12701_yujm_2020_00843 crossref_primary_10_12701_yujm_2020_00843 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-Oct |
PublicationDateYYYYMMDD | 2021-10-01 |
PublicationDate_xml | – month: 10 year: 2021 text: 2021-Oct |
PublicationDecade | 2020 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Journal of yeungnam medical science |
PublicationTitleAlternate | Yeungnam Univ J Med |
PublicationYear | 2021 |
Publisher | Yeungnam University College of Medicine 영남대학교 의과대학 |
Publisher_xml | – name: Yeungnam University College of Medicine – name: 영남대학교 의과대학 |
References | ref13 ref12 ref15 ref14 ref10 ref2 ref17 ref16 ref7 ref9 ref4 ref3 ref6 ref5 Eriksson (ref8) 1989 Benjamin (ref1) 2019 Ottesen (ref11) 2017 |
References_xml | – ident: ref16 doi: 10.1016/j.amjcard.2016.05.018 – ident: ref4 doi: 10.4070/kcj.2017.0009 – start-page: e56 volume-title: Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association year: 2019 ident: ref1 – ident: ref3 doi: 10.3346/jkms.2019.34.e133 – ident: ref5 doi: 10.4070/kcj.2018.0349 – ident: ref6 doi: 10.4070/kcj.2018.0373 – ident: ref13 doi: 10.1093/eurjhf/hfq055 – start-page: e003675 volume-title: Glycosylated chromogranin A in heart failure: implications for processing and cardiomyocyte calcium homeostasis year: 2017 ident: ref11 – start-page: 325 volume-title: Chromogranins: new sensitive markers for neuroendocrine tumors year: 1989 ident: ref8 – ident: ref15 doi: 10.1111/j.1527-5299.2004.03310.x – ident: ref7 doi: 10.1152/ajpendo.1991.260.2.e243 – ident: ref10 doi: 10.1053/euhj.2001.2977 – ident: ref17 doi: 10.4070/kcj.2018.0351 – ident: ref14 doi: 10.1080/08880010802435393 – ident: ref9 doi: 10.1093/eurheartj/ehn513 – ident: ref12 doi: 10.1016/j.ahj.2006.05.008 – ident: ref2 doi: 10.4070/kcj.2016.0419 |
SSID | ssj0002217211 ssj0002808916 |
Score | 2.162462 |
Snippet | Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value... Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical... Background Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and... |
SourceID | nrf doaj unpaywall pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 337 |
SubjectTerms | biomarkers chromogranin a heart failure Original prognosis 의학일반 |
SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdG9wAvDMRXGKCAeAEpbeI4jv1YEFNBYtoDRePJcvyxde2Sqm2Eyl_PnZtWFBBoL4mU-CL77uy7X3y-I-S1szaV1PDEeaMTxqlMqgzAis41lanJnQmHxD6f8tGYfTovzg9IsT0LE8Iqk6v19TJs47fzWaPtYG79YN1eXYNMKR6EFgwQoPW3yCHHfaUeORyfng2_hUJygiUp2LBuS5KWaRZI-0jaD6R7Jihk6gfDUi_835zMP2Mlb7f1XK-_69nsF0N0ckS-boewiT-Z9ttV1Tc_fsvueOMx3iN3O9c0Hm506T45cPUDMjpbNBiLB8_izYnKuPGxucQovguwc5M6HsZw6fKzLmP8sRtr065cjMWyV7HXEwx9f0jGJx--vB8lXfWFxKBlS8DuW8ZZBStpaaVkouIlYDtfgscIuLnyVnLLXC5T4XVqqKXai1xnrgA3wBiTPyK9uqndExLb0nLKilJaCXiSOeGyCtw4oLVWUEkjMtgKRJkuNTlWyJgphCgoQoWcUcgZFTgTkTc7ivkmLcc_2r5DGe_aYULt8ACYr7r5qbhPcy0AXFnwIDOeam41Qkft8qywporIK9AQNTWTQI_3i0ZNFwpgx0clRck4LyLycqtACmYpbr3o2jXtUiEM50IAFo7I441C7fqDORhzgPERKfdUba_D-2_qyWXIBC7gm7DiRuTtTin_y46nN2l8TO5QDOIJ0YvPSG-1aN1z8MJW1Ytuzv0EJFQvyA priority: 102 providerName: Unpaywall |
Title | Prognostic impact of chromogranin A in patients with acute heart failure |
URI | https://www.ncbi.nlm.nih.gov/pubmed/34233402 https://www.proquest.com/docview/2549688448 https://pubmed.ncbi.nlm.nih.gov/PMC8688787 https://www.e-jyms.org/upload/pdf/yujm-2020-00843.pdf https://doaj.org/article/6f03a8974d514160a6da9560ae315dcb https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002768387 |
UnpaywallVersion | publishedVersion |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Journal of Yeungnam Medical Science, 2021, 38(4), , pp.337-343 |
journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2384-0293 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0002808916 issn: 2384-0293 databaseCode: DOA dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2384-0293 dateEnd: 20221231 omitProxy: true ssIdentifier: ssj0002217211 issn: 2384-0293 databaseCode: DOA dateStart: 20170101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2384-0293 dateEnd: 20211231 omitProxy: true ssIdentifier: ssj0002217211 issn: 2384-0293 databaseCode: M~E dateStart: 20150101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2384-0293 dateEnd: 20211231 omitProxy: true ssIdentifier: ssj0002217211 issn: 2384-0293 databaseCode: RPM dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBUlPbSX0tIvp2lQSy8tmLUlWZaO29KwLTTk0IX0JGR9JJssdtisCfn3nZGdZZeW5tKLDbZkxGikN88aPRHyIXhfaOZkHqKzuZBM500JZMVyy3TheHBpk9iPYzmbi--n1enWUV-YEzbIAw-Gm8hYcKsg6vUA7aUsrPQWY3obeFl51-DsCzC2RaYukqhLojbjuiSri3Jy21_gznOGqVxK8B0cSnL9gC7tKv4t0vwzYfJR317Z2xu7XG6h0dFT8mQMI-l0aP4z8iC0z8nsZNVh3hw8o8PuR9pF6s4x4-4MMGnR0imFy6ilek3xJyy1rl8Higdbr2m0C0xTf0HmR19_fpnl40kJuUMUygGjvZCigVmv9loL1cgaeFisIboDjttEr6UXgetCRVs45pmNitsyVADZzjn-kuy1XRteE-prL5moau01cD8RVCgbCLmgrveKaZaRyZ3djBtlxPE0i6VBOoGWNmhpg5Y2ydIZ-bipcTVIaPyj7Gfsik05FL9OD8AlzOgS5j6XyMh76Ehz6RapPt7POnO5MkARvhmtaiFllZF3d_1sYEThMoltQ9dfG6TMUingrRl5NfT7pj2ol8iBcmek3vGInQbvvmkX50m1W8E3YXbMyKeN79xrjv3_YY435DHDRJyUgXhA9tarPryFSGrdHKZBc0gezo9Ppr9-A-i-G1A |
linkProvider | Directory of Open Access Journals |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdG9wAvDMRXGKCAeAEpbeI4jv1YEFNBYtoDRePJcvyxde2Sqm2Eyl_PnZtWFBBoL4mU-CL77uy7X3y-I-S1szaV1PDEeaMTxqlMqgzAis41lanJnQmHxD6f8tGYfTovzg9IsT0LE8Iqk6v19TJs47fzWaPtYG79YN1eXYNMKR6EFgwQoPW3yCHHfaUeORyfng2_hUJygiUp2LBuS5KWaRZI-0jaD6R7Jihk6gfDUi_835zMP2Mlb7f1XK-_69nsF0N0ckS-boewiT-Z9ttV1Tc_fsvueOMx3iN3O9c0Hm506T45cPUDMjpbNBiLB8_izYnKuPGxucQovguwc5M6HsZw6fKzLmP8sRtr065cjMWyV7HXEwx9f0jGJx--vB8lXfWFxKBlS8DuW8ZZBStpaaVkouIlYDtfgscIuLnyVnLLXC5T4XVqqKXai1xnrgA3wBiTPyK9uqndExLb0nLKilJaCXiSOeGyCtw4oLVWUEkjMtgKRJkuNTlWyJgphCgoQoWcUcgZFTgTkTc7ivkmLcc_2r5DGe_aYULt8ACYr7r5qbhPcy0AXFnwIDOeam41Qkft8qywporIK9AQNTWTQI_3i0ZNFwpgx0clRck4LyLycqtACmYpbr3o2jXtUiEM50IAFo7I441C7fqDORhzgPERKfdUba_D-2_qyWXIBC7gm7DiRuTtTin_y46nN2l8TO5QDOIJ0YvPSG-1aN1z8MJW1Ytuzv0EJFQvyA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+impact+of+chromogranin+A+in+patients+with+acute+heart+failure&rft.jtitle=Yeungnam+University+journal+of+medicine&rft.au=Kim%2C+Hong+Nyun&rft.au=Yang%2C+Dong+Heon&rft.au=Park%2C+Bo+Eun&rft.au=Park%2C+Yoon+Jung&rft.date=2021-10-01&rft.pub=Yeungnam+University+College+of+Medicine&rft.eissn=2384-0293&rft.volume=38&rft.issue=4&rft.spage=337&rft.epage=343&rft_id=info:doi/10.12701%2Fyujm.2020.00843&rft_id=info%3Apmid%2F34233402&rft.externalDocID=PMC8688787 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2384-0293&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2384-0293&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2384-0293&client=summon |